Evidence map›Paper›PMID 36278154›Full record

SynthesisFrontiers in pharmacology2022

Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis.

Tengteng Jian, Yang Zhan, Kebang Hu, Liang He, Sunmeng Chen, Rui Hu, Ji Lu

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Combination therapy for high-volumeFrontiers in pharmacology · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tengteng JianDepartment of Urology, The First Hospital of Jilin University, Changchun, China.
Yang ZhanSchool of Life Sciences, Jilin University, Changchun, China.
Kebang HuDepartment of Urology, The First Hospital of Jilin University, Changchun, China.
Liang HeDepartment of Urology, The First Hospital of Jilin University, Changchun, China.
Sunmeng ChenDepartment of Urology, The First Hospital of Jilin University, Changchun, China.
Rui HuDepartment of Urology, The First Hospital of Jilin University, Changchun, China.
Ji LuDepartment of Urology, The First Hospital of Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Docetaxelmetastatic hormone-sensitive prostate cancernetwork meta-analysissystemic therapytriplet therapy

Identifiers

PMID36278154
PMCPMC9582339
OpenAlexW4302303604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.